Aidoc Secures $150M in Funding to Expand Clinical AI Solutions

Healthcare AI company Aidoc has raised $150 million in new financing to expand its clinical AI solutions into oncology and cardiovascular disease. The funding round, led by General Catalyst and Square Peg, with participation from NVentures (NVIDIA's venture capital arm) and four major U.S. health systems, brings Aidoc's total funding to $370 million.

AI-Powered Healthcare Transformation

Aidoc's CARE (Clinical AI Reasoning Engine) foundation model is at the forefront of the company's innovation efforts. The model, which has already powered two FDA-cleared solutions, assists physicians in clinical decision-making. Aidoc's technology is currently supporting care for over 45 million patients annually across more than 150 health systems, with plans to expand to 100 million patients in three years.

Elad Walach, CEO of Aidoc, emphasized the company's mission: "Our mission is to reduce diagnostic errors and improve patient outcomes. CARE compresses decades of roadmap into years—bringing forward a future where AI supports every patient encounter, helping physicians provide the care they believe their patients deserve."

Enterprise-Grade AI Platform and Strategic Collaborations

Aidoc is doubling down on its enterprise-grade AI platform, aiOS, designed to enable health systems to deploy and govern multiple AI solutions responsibly. The platform hosts both Aidoc and external solutions, with 69% of customers currently running non-Aidoc models on aiOS.

Strategic collaborations with Amazon Web Services and NVIDIA are enhancing Aidoc's capabilities. The company is working with NVIDIA to develop BRIDGE (Blueprint for Resilient Integration and Deployment of Guided Excellence), a set of guidelines for AI implementation in healthcare.

Expanding Clinical Impact

Aidoc's clinical AI solutions aim to improve decision-making at the point of care by flagging suspected high-risk findings, automating follow-ups, and expediting patient care. The company plans to transition all its models to the CARE foundation, which is expected to cover 90% of clinically relevant diseases, including cancer and cardiovascular conditions, within three years.

Michael Braginsky, co-founder and CTO of Aidoc, highlighted the importance of model accuracy in healthcare: "Foundation models will soon be as ubiquitous in healthcare as ChatGPT is in general use. Building is an enormous lift – it requires top-tier talent, powerful infrastructure, deep real-world insight and sustained funding."

As Aidoc continues to expand its reach and capabilities, the company is poised to play a significant role in shaping the future of AI-powered healthcare, aiming to improve patient outcomes and alleviate clinician burnout through innovative technology solutions.